Perceptive Enhances Capabilites Through Alliance with Biospective

Boston, MA, July 9, 2009-Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced that it has enhanced its capabilities with respect to processing and analysis of medical images for central nervous system (CNS) and oncology related clinical trials through an alliance with Biospective, Inc. Through this alliance, Perceptive Informatics will use Biospective’s specialized medical imaging process and analysis software to supplement its existing technology in support of independent reviews of imaging data for both exploratory and large-scale, multi-center studies.

Experts from Perceptive Informatics will discuss these enhanced capabilities at Booth #333 in the exhibit hall during the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD), to be held July 11–16, 2009 in Vienna, Austria. James Paskavitz, M.D., Medical Director, Perceptive Informatics will be available at ICAD to discuss a poster presentation regarding a medical imaging methodology developed by Perceptive Informatics, which provides a new approach to monitor brain atrophy in Alzheimer’s disease and potential treatment effects with the goal of accelerating decisions about Alzheimer’s compounds in development.

“With CNS and oncology research growing at a fast pace, Perceptive Informatics is focused on expanding its capabilities to help clients use medical imaging as an endpoint, or biomarker, to assess efficacy and safety of new treatments in these important therapeutic areas,” said Kenneth G. Faulkner, Ph.D., Vice President of Medical Imaging, Perceptive Informatics. “Our alliance with Biospective expands Perceptive’s ability to provide sophisticated imaging capabilities, which combined with our in-depth therapeutic expertise is focused on improving the productivity and efficiency of clinical studies.”

According to Barry J. Bedell, M.D., Ph.D., Chief Operating Officer and Chief Science Officer, Biospective, “We are pleased to work closely with Perceptive to provide clinical study sponsors with high medical image quality as well as advanced image processing and analysis capabilities for early- and late-phase CNS and oncology trials.”

Biospective supplements the medical imaging capabilities of Perceptive Informatics by providing software solutions tailored for CNS and oncology studies, including specialized Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) techniques. The Medical Imaging Group of Perceptive Informatics offers a range of capabilities in the application of imaging techniques from early clinical development through peri-approval studies. The medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology imaging.

About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has over 9,400 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC on May 8, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.